Synthesis of semi-biodegradable crosslinked microspheres for the delivery of 1,25 dihydroxyvitamin D sub(3) for the treatment of hepatocellular carcinoma

It has been demonstrated that 1,25 dihydroxyvitamin D sub(3) (1,25(OH) sub(2)VD sub(3)) can inhibit the proliferation of cancer cells, including colorectal and hepatocellular cells which are mainly responsible for liver cancer. However, the use of 1,25(OH) sub(2)VD sub(3) is hampered due to the deve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European polymer journal 2007-05, Vol.43 (5), p.1754-1767
Hauptverfasser: Nguyen, TLU, Tey, SY, Pourgholami, M H, Morris, D L, Davis, T P, Barner-Kowollik, C, Stenzel, M H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It has been demonstrated that 1,25 dihydroxyvitamin D sub(3) (1,25(OH) sub(2)VD sub(3)) can inhibit the proliferation of cancer cells, including colorectal and hepatocellular cells which are mainly responsible for liver cancer. However, the use of 1,25(OH) sub(2)VD sub(3) is hampered due to the development of hypercalcaemia. We hereby report a promising technique in liver cancer treatment by utilizing crosslinked microspheres prepared by polymerization as a carrier to control the release of 1,25(OH) sub(2)VD sub(3) or hydrophobic drug in general at targeted sites over a long period. Microspheres in the size range of 35 mu m were prepared and the drug was loaded to these poly(vinyl neodecanoate-crosslinked-ethyleneglycol dimethacrylate) microspheres after polymerization. The release study has shown that up to 1% of the drug was released after 40 days. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and direct contact cytotoxicity assay using HT-20 and L929 confirm the non-toxicity of these spheres.
ISSN:0014-3057
DOI:10.1016/j.eurpolymj.2007.02.019